Are SPACs Better Than Traditional IPOs?
Outcome Capital’s Managing Director Paul Mieyal, Ph.D., CFA was interviewed by BioSpace for his views on the recent popularity of SPACs in the biotech space. The interview covers historical perspective, current market dynamics, and outlook for the next year.
Published: Mar 10, 2021 By Kate Goodwin
Outcome Capital’s Managing Director Paul Mieyal, Ph.D., CFA was interviewed by BioSpace for his views on the recent popularity of SPACs in the biotech space. The interview covers historical perspective, current market dynamics, and outlook for the next year.
News
Outcome Capital and YAFO Capital Announce Strategic Partnership to Expand Global Strategic and Financial Services to Biopharma and Healthcare Clients
The collaboration will allow the partners to globally expand financial advisory services and cross-border transactions for life sciences and biopharmaceutical client companies Boston & Shanghai – September 14, 2023. Outcome Capital, a specialized life science advisory and investment banking firm, and YAFO Capital, a Shanghai-based boutique investment banking and advisory firm, announced that the companies […]
Read MoreResources
Outcome Capital Life Sciences Pulse, August 2023
Outcome Capital Life Science Market Pulse August 2023 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2023. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy
